• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brainstorm Cell Therapeutics

Anika CEO retires after two decades; president assumes corner office | Personnel Moves – March 13, 2018

March 13, 2018 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) announced this month that CEO Charles Sherwood plans to retire after working for Anika for nearly twenty years. Joseph Darling, who has been Anika’s president since July 2017, will take his place in the corner office. Darling has previously served in executive leadership roles across an array of medtech companies like Abbott (NYSE:ABT), Baxter (NYSE:BAX) […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: abbott, alucentmedical, Anika Therapeutics Inc., Baxter, BioTime, Brainstorm Cell Therapeutics, Kala Pharmaceuticals, medherant, milestonescientific, pertinaxpharma, smith&nephew, West Pharmaceutical Services

Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018

February 26, 2018 By Sarah Faulkner

Proteus Digital Health

Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. “Proteus has created a compelling solution to a problem that has plagued the pharmaceutical industry for decades: […]

Filed Under: Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Allergan, Anthem, BioCorRx, Brainstorm Cell Therapeutics, Chrono Therapeutics, infusystem, Proteus Digital Health, Reva Medical, zynosolutions

OncoSec Medical names new CEO | Personnel Moves – Nov. 9, 2017

November 9, 2017 By Sarah Faulkner

OncoSec Medical

OncoSec Medical (NSDQ:ONCS)  announced earlier this week that the company’s co-founder, Punit Dhillon, would step down as CEO and continue to serve as president while Daniel O’Connor takes over the corner office. O’Connor joined OncoSec’s board of directors in September this year. “We are pleased to welcome Dan to OncoSec at this important time, and believe […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals, Anika Therapeutics Inc., bostonbiomedical, Brainstorm Cell Therapeutics, DelMar Pharmaceuticals, Express Scripts, GlaxoSmithKline plc, OncoSec Medical, Pulmatrix Inc.

BrainStorm enrolls first ALS patient in late-stage NurOwn trial

October 16, 2017 By Sarah Faulkner

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that the first patients have been enrolled in its Phase III trial evaluating NurOwn as a treatment for amyotrophic lateral sclerosis, or ALS, at Massachusetts General Hospital and UC Irvine Medical Center. The trial, which is slated to enroll 200 patients, is designed to include the pre-specified patient subgroups who […]

Filed Under: Clinical Trials, Featured, Neurological, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

Brainstorm adds UCal Irvine Medical Center to late-stage NurOwn trial

July 25, 2017 By Sarah Faulkner

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis. This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. […]

Filed Under: Clinical Trials, Featured, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics wins $16m grant for pivotal NurOwn ALS study

July 21, 2017 By Fink Densford

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis. Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Funding Roundup, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

Brainstorm lands $2.1m Israeli grant for NurOwn stem cell therapy

June 13, 2017 By Sarah Faulkner

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it landed a $2.1 million grant from the Israel Innovation Authority. The funds are slated to support the development of Brainstorm’s NurOwn mesenchymal stem cell-based platform for the treatment of neurodegenerative diseases, including ALS. This is the 10th year that Brainstorm has won grant support from the Israeli office […]

Filed Under: Featured, Funding Roundup, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

BrainStorm seeks early Health Canada nod for NurOwn treatment

February 22, 2017 By Sarah Faulkner

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) is reportedly seeking early regulatory approval in Canada for its NurOwn stem cell treatment for patients with ALS. The company told Reuters this week that it has inked an agreement with a Canadian non-profit organization, CCRM, that helps to support the development of regenerative medicine. The organization plans to help BrainStorm meet Canadian regulatory requirements […]

Filed Under: Featured, Regulatory/Compliance, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

Brainstorm’s NurOwn stem cell treatment for ALS readies for phase III

December 19, 2016 By Sarah Faulkner

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today that it’s preparing for a phase III trial of its NurOwn stem cell treatment, after meeting with the FDA about a biologic license application. The company is developing adult stem cell therapies derived from autologous bone marrow cells to treat neurodegenerative diseases, such as ALS. Hackensack, N.J.-based Brainstorm is planning […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Neurological, Stem Cells Tagged With: Brainstorm Cell Therapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS